Boston Life Sciences, Inc. to Present at the 8th Annual Rodman & Renshaw Annual Healthcare Conference
31 Octobre 2006 - 5:12PM
PR Newswire (US)
HOPKINTON, Mass., Oct. 31 /PRNewswire-FirstCall/ -- Boston Life
Sciences, Inc. (NASDAQ:BLSI) today announced that Peter Savas,
Chairman and Chief Executive Officer of Boston Life Sciences, Inc.,
will be presenting a Company update at the Rodman & Renshaw
Annual Healthcare Conference on Monday, November 6 from 4:35pm -
4:55pm EST in the Holmes II room. The conference is being held from
November 6-8 at the New York Palace Hotel in New York City, NY. The
Boston Life Sciences presentation will be available by webcast.
Access to the webcast will be available within the Investor
Relations section of the Boston Life Sciences website at
http://www.bostonlifesciences.com/. About Boston Life Sciences,
Inc. Boston Life Sciences, Inc. (BLSI) is engaged in the research
and clinical development of diagnostic and therapeutic products for
central nervous system (CNS) disorders. ALTROPANE(R) molecular
imaging agent is in Phase III clinical trials for the diagnosis of
Parkinsonian Syndrome (PS) and Phase II clinical trials for the
diagnosis of Attention Deficit Hyperactivity Disorder (ADHD). The
Company's research and pre-clinical CNS programs include Inosine
for the treatment of stroke, a DAT blocker for the treatment of
Parkinson's disease and a second generation technetium-based
molecular imaging agent for PS and ADHD. BLSI's current research
collaborations include Harvard Medical School and Children's
Hospital Boston. Contact: Sharon Correia -- 508-497-2360 ext 224
Boston Life Sciences, Inc. DATASOURCE: Boston Life Sciences, Inc.
CONTACT: Sharon Correia of Boston Life Sciences, Inc.,
+1-508-497-2360, ext. 224, Web site:
http://www.bostonlifesciences.com/
Copyright
Boston Life Sciences (NASDAQ:BLSI)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Boston Life Sciences (NASDAQ:BLSI)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Boston Life Sciences (MM) (NASDAQ): 0 recent articles
Plus d'articles sur Boston Life Sciences (MM)